ScholarIQanswers from OpenAlex & ORCID
Jeffrey S. Weber
ResearcherPublications, citations & collaboration network
Jeffrey S. Weber is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Jeffrey S. Weber have?
ScholarIQindexed works
Jeffrey S. Weber has 1,047 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Jeffrey S. Weber have?
ScholarIQcitation count
Jeffrey S. Weber has 96,068 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Jeffrey S. Weber?
ScholarIQh-index
Jeffrey S. Weber has an h-index of 122 in OpenAlex.
What is the i10-index of Jeffrey S. Weber?
ScholarIQi10-index
Jeffrey S. Weber has an i10-index of 393 in OpenAlex.
What is the ORCID of Jeffrey S. Weber?
ScholarIQorcid
The ORCID for Jeffrey S. Weber is on the source record.
What is the OpenAlex record for Jeffrey S. Weber?
ScholarIQopenalex
The OpenAlex for Jeffrey S. Weber is on the source record.
What are the most-cited papers on Jeffrey S. Weber?
ScholarIQmost cited works
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert, L. Thomas, Igor Bondarenko, Steven O’Day, Jeffrey S. Weber, Claus Garbe, Célèste Lebbé, Jean‐François Baurain, Alessandro Testori, Jean‐Jacques Grob, Neville Davidson, Jon Richards, Michele Maio, Axel Hauschild, Wilson H. Miller, Pere Gascón, Michal Lotem, Kaan Harmankaya, Ramy Ibrahim, Stephen Francis, Tai‐Tsang Chen, Rachel Humphrey, Axel Hoos, Jedd D. Wolchok
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer, Christina Lacchetti, Bryan J. Schneider, Michael B. Atkins, Kelly Brassil, Jeffrey M. Caterino, Ian Chau, Marc S. Ernstoff, Jennifer M. Gardner, Pamela Ginex, Sigrun Hallmeyer, Jennifer Holter Chakrabarty, Natasha B. Leighl, Jennifer S. Mammen, David F. McDermott, Aung Naing, Loretta J. Nastoupil, Tanyanika Phillips, Laura Porter, Igor Puzanov, Cristina Reichner, Bianca Santomasso, Carole Seigel, Alexander I. Spira, María E. Suarez‐Almazor, Yinghong Wang, Jeffrey S. Weber, Jedd D. Wolchok, John A. Thompson
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber, Sandra P. D’Angelo, David R. Minor, F. Stephen Hodi, Ralf Gutzmer, Bart Neyns, Christoph Höeller, Nikhil I. Khushalani, Wilson H. Miller, Christopher D. Lao, Gerald P. Linette, L. Thomas, Paul Lorigan, Kenneth F. Grossmann, Jessica C. Hassel, Michele Maio, Mario Sznol, Paolo A. Ascierto, Peter Mohr, Bartosz Chmielowski, Alan H. Bryce, Inge Marie Svane, Jean‐Jacques Grob, Angela M. Krackhardt, Christine E. Horak, Alexandre Lambert, Arvin Yang, James Larkin
Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
Paolo A. Ascierto, Michele Del Vecchio, Mario Mandalà, Helen Gogas, Ana Arance, Stéphane Dalle, C. Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion‐Sileni, Iván Márquez‐Rodas, Marcus O. Butler, Michele Maio, Mark R. Middleton, Luis de la Cruz‐Merino, Petr Arenberger, Victoria Atkinson, Andrew Hill, Leslie A. Fecher, Michael Millward, Nikhil I. Khushalani, Paola Queirolo, Maurice Lobo, Veerle de Pril, John T. Loffredo, James Larkin, Jeffrey S. Weber
12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?
Jane L. Messina, David Fenstermacher, Steven A. Eschrich, Xiaotao Qu, Anders Berglund, Mark C. Lloyd, Michael J. Schell, Vernon K. Sondak, Jeffrey S. Weber, James J. Mulé